Abstract: The present invention relates to parenteral compositions comprising methylene blue, water and one or more pH regulating agents. The present invention also relates to processes for preparing such compositions.

Abstract: The present invention relates to stable, aqueous, parenteral solutions comprising diclofenac and polyvinylpyrrolidone, wherein the solutions are for parenteral (subcutaneous, intravenous and/or intramuscular) administration to a mammal.

Abstract: The present invention provides a stable pharmaceutical composition comprising apomorphine and one or more pharmaceutically acceptable carriers in an injectable device. The present invention also provides a process for preparing the stable pharmaceutical composition.

Abstract: The present invention relates to lyophilized pharmaceutical compositions of copper histidinate and one or more pharmaceutically acceptable excipients. It also relates to processes for preparing such compositions.

Abstract: The present invention relates to stable, aqueous, parenteral solutions comprising diclofenac and polyvinylpyrrolidone, wherein the solutions are for parenteral (subcutaneous, intravenous and/or intramuscular) administration to a mammal.

Abstract: The present invention relates to stable, aqueous, parenteral solutions comprising diclofenac and polyvinylpyrrolidone, wherein the solutions are for parenteral (subcutaneous, intravenous and/or intramuscular) administration.

Abstract: The present invention relates to parenteral compositions comprising methylene blue, water and one or more pH regulating agents. The present invention also relates to processes for preparing such compositions.

Abstract: Distributing electromagnetic radiation in a reaction chamber may involve causing at least some electromagnetic radiation from at least one electromagnetic radiation emitter to be refracted by at least one lens into the reaction chamber as refracted electromagnetic radiation skewed laterally relative to a longitudinal direction of the reaction chamber and/or relative to the at least some electromagnetic radiation from the at least one electromagnetic radiation emitter.

Abstract: The present invention relates to stable, aqueous, parenteral solutions comprising diclofenac and polyvinylpyrrolidone, wherein the solutions are for parenteral (subcutaneous, intravenous and/or intramuscular) administration.

Abstract: The invention relates to stable, aqueous, parenteral solutions comprising one or more nonsteroidal anti-inflammatory drugs (NSAIDs) and polyvinylpyrrolidone. The present invention also relates to processes for processes preparing such solutions.

Abstract: The present invention relates to sterile injectable compositions comprising melphalan and one or more phospholipids. The present invention also relates to processes for preparing the sterile injectable compositions.

Abstract: The present invention relates to sterile injectable compositions comprising carfilzomib and one or more phospholipids. The present invention also relates to processes for preparing the sterile injectable compositions.

Abstract: The present invention relates to stable pharmaceutical compositions of micafungin or a pharmaceutically acceptable salt thereof suitable for parenteral administration. In particular, the invention relates to stable injectable compositions of micafungin or a pharmaceutically acceptable salt thereof which does not require reconstitution. The invention also relates to processes for preparing such compositions and use thereof for the treatment of fungal infections.

Abstract: The present invention relates to stable aqueous pharmaceutical compositions of voriconazole or a pharmaceutically acceptable salt thereof suitable for parenteral administration. In particular, the invention relates to ready-to-use stable injectable compositions of voriconazole or a pharmaceutically acceptable salt thereof. The invention also relates to processes for the preparation of such compositions and use thereof for the treatment of fungal infections.

Abstract: Methods and apparatus provide for an artboard generator that detects a selection to create a new artboard on a digital canvas. The artboard generator provides a transparent rendition of the new artboard on the digital canvas and performs a placement operation of the new artboard. Upon completion of the placement operation, the artboard generator converts the transparent rendition of the new artboard to an opaque rendition of the new artboard. The artboard generator detects a selection to create a second new artboard. The artboard generator defines characteristics of the second new artboard in accordance with characteristics of the resized new artboard. The artboard generator provides a transparent rendition of the second new artboard and performs a placement operation of the second new artboard. Upon completion of the placement operation, the artboard generator converts the second new artboard from a transparent rendition to an opaque rendition.

Abstract: A method for generating a standard cell layout pattern for standard cell placement in an integrated circuit uses a congestion map. First, congestion zones are identified in a congestion map generated by an Electronic Design Automation (EDA) application. Next, routing tracks data corresponding to bounding boxes belonging to the congestion zones are used to calculate values of average vertical and horizontal congestion. Subsequently, a value of modified standard cell density is calculated based on the values of average vertical and horizontal congestion, and an unmodified standard cell density. The dimensions of a layout pattern unit are calculated using the value of the modified standard cell density and the width of standard cells. Various layout pattern units then are placed adjacent to one another to form a standard cell layout pattern.

Abstract: A method for generating a standard cell layout pattern for standard cell placement in an integrated circuit uses a congestion map. First, congestion zones are identified in a congestion map generated by an Electronic Design Automation (EDA) application. Next, routing tracks data corresponding to bounding boxes belonging to the congestion zones are used to calculate values of average vertical and horizontal congestion. Subsequently, a value of modified standard cell density is calculated based on the values of average vertical and horizontal congestion, and an unmodified standard cell density. The dimensions of a layout pattern unit are calculated using the value of the modified standard cell density and the width of standard cells. Various layout pattern units then are placed adjacent to one another to form a standard cell layout pattern.

Abstract: The invention provides two crystalline forms A and B of the skeletal muscle relaxant and anxiolytic agent, Metaxalone of formula (I), and a process for preparation thereof. The two crystalline forms A and B are bioavailable. The invention further provides pharmaceutical compositions comprising the two bioavailable crystalline forms, useful for the relief of discomforts associated with acute, painful musculoskeletal conditions.